Table of Contents Author Guidelines Submit a Manuscript
Mediators of Inflammation
Volume 2012, Article ID 147354, 8 pages
http://dx.doi.org/10.1155/2012/147354
Review Article

Atherosclerosis and Rheumatoid Arthritis: More Than a Simple Association

Department of Rheumatology, University and IRCCS Foundation Policlinico San Matteo, Viale Golgi 19, 27100 Pavia, Italy

Received 25 June 2012; Accepted 10 July 2012

Academic Editor: Miguel A. González-Gay

Copyright © 2012 Lorenzo Cavagna et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. C. Meune, E. Touzé, L. Trinquart, and Y. Allanore, “High risk of clinical cardiovascular events in rheumatoid arthritis: levels of associations of myocardial infarction and stroke through a systematic review and meta-analysis,” Archives of Cardiovascular Diseases, vol. 103, no. 4, pp. 253–261, 2010. View at Publisher · View at Google Scholar · View at Scopus
  2. L. Cavagna, R. Caporali, L. Bogliolo, and C. Montecucco, “Cardiovascular involvement in rheumatoid arthritis,” Progressi in Reumatologia, vol. 3, no. 1, pp. 72–76, 2002. View at Google Scholar · View at Scopus
  3. H. Mirjafari, A. Al-Husain, and I. N. Bruce, “Cardiovascular risk factors in inflammatory arthritis,” Current Opinion in Lipidology, vol. 22, no. 4, pp. 296–301, 2011. View at Publisher · View at Google Scholar · View at Scopus
  4. F. Montecucco and F. Mach, “Atherosclerosis is an inflammatory disease,” Seminars in Immunopathology, vol. 31, no. 1, pp. 1–3, 2009. View at Publisher · View at Google Scholar · View at Scopus
  5. G. Howard, L. E. Wagenknecht, G. L. Burke et al., “Cigarette smoking and progression of atherosclerosis: the atherosclerosis risk in communities (ARIC) study,” JAMA, vol. 279, no. 2, pp. 119–124, 1998. View at Publisher · View at Google Scholar · View at Scopus
  6. H. Källberg, B. Ding, L. Padyukov et al., “Smoking is a major preventable risk factor for rheumatoid arthritis: estimations of risks after various exposures to cigarette smoke,” Annals of the Rheumatic Diseases, vol. 70, no. 3, pp. 508–511, 2011. View at Publisher · View at Google Scholar · View at Scopus
  7. Z. Szekanecz, G. Kerekes, H. Dér et al., “Accelerated atherosclerosis in rheumatoid arthritis,” Annals of the New York Academy of Sciences, vol. 1108, pp. 349–358, 2007. View at Publisher · View at Google Scholar · View at Scopus
  8. P. W. Pemberton, Y. Ahmad, H. Bodill et al., “Biomarkers of oxidant stress, insulin sensitivity and endothelial activation in rheumatoid arthritis: a cross-sectional study of their association with accelerated atherosclerosis,” BMC Research Notes, vol. 2, article 83, 2009. View at Publisher · View at Google Scholar · View at Scopus
  9. N. J. Goodson, D. P. M. Symmons, D. G. I. Scott, D. Bunn, M. Lunt, and A. J. Silman, “Baseline levels of C-reactive protein and prediction of death from cardiovascular disease in patients with inflammatory polyarthritis: a ten-year followup study of a primary care-based inception cohort,” Arthritis and Rheumatism, vol. 52, no. 8, pp. 2293–2299, 2005. View at Publisher · View at Google Scholar · View at Scopus
  10. H. Maradit-Kremers, C. S. Crowson, P. J. Nicola et al., “Increased unrecognized coronary heart disease and sudden deaths in rheumatoid arthritis: a population-based cohort study,” Arthritis and Rheumatism, vol. 52, no. 2, pp. 402–411, 2005. View at Publisher · View at Google Scholar · View at Scopus
  11. I. A. Ku, J. B. Imboden, P. Y. Hsue, and P. Ganz, “Rheumatoid arthritis—a model of systemic inflammation driving atherosclerosis,” Circulation Journal, vol. 73, no. 6, pp. 977–985, 2009. View at Publisher · View at Google Scholar · View at Scopus
  12. C. Gonzalez-Juanatey, J. Llorca, A. Testa, J. Revuelta, C. Garcia-Porrua, and M. A. Gonzalez-Gay, “Increased prevalence of severe subclinical atherosclerotic findings in long-term treated rheumatoid arthritis patients without clinically evident atherosclerotic disease,” Medicine, vol. 82, no. 6, pp. 407–413, 2003. View at Publisher · View at Google Scholar · View at Scopus
  13. D. H. Solomon, E. W. Karlson, E. B. Rimm et al., “Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis,” Circulation, vol. 107, no. 9, pp. 1303–1307, 2003. View at Publisher · View at Google Scholar · View at Scopus
  14. B. J. Van Lenten, S. T. Reddy, M. Navab, and A. M. Fogelman, “Understanding changes in high density lipoproteins during the acute phase response,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 26, no. 8, pp. 1687–1688, 2006. View at Publisher · View at Google Scholar · View at Scopus
  15. N. Tanimoto, Y. Kumon, T. Suehiro et al., “Serum paraoxonase activity decreases in rheumatoid arthritis,” Life Sciences, vol. 72, no. 25, pp. 2877–2885, 2003. View at Publisher · View at Google Scholar · View at Scopus
  16. G. Baskol, H. Demir, M. Baskol et al., “Assessment of paraoxonase 1 activity and malondialdehyde levels in patients with rheumatoid arthritis,” Clinical Biochemistry, vol. 38, no. 10, pp. 951–955, 2005. View at Publisher · View at Google Scholar · View at Scopus
  17. E. Profumo, M. Di Franco, B. Buttari et al., “Biomarkers of subclinical atherosclerosis in patients with autoimmune disorders,” Mediators of Inflammation, vol. 2012, Article ID 503942, 8 pages, 2012. View at Publisher · View at Google Scholar · View at Scopus
  18. J. Leipe, M. Grunke, C. Dechant et al., “Role of Th17 cells in human autoimmune arthritis,” Arthritis and Rheumatism, vol. 62, no. 10, pp. 2876–2885, 2010. View at Publisher · View at Google Scholar · View at Scopus
  19. T. van Es, G. H. M. van Puijvelde, O. H. Ramos et al., “Attenuated atherosclerosis upon IL-17R signaling disruption in LDLr deficient mice,” Biochemical and Biophysical Research Communications, vol. 388, no. 2, pp. 261–265, 2009. View at Publisher · View at Google Scholar · View at Scopus
  20. J. Liang, Z. Zheng, M. Wang et al., “Myeloperoxidase (MPO) and interleukin-17 (IL-17) plasma levels are increased in patients with acute coronary syndromes,” Journal of International Medical Research, vol. 37, no. 3, pp. 862–866, 2009. View at Google Scholar · View at Scopus
  21. W. Marder, S. Khalatbari, J. D. Myles et al., “Interleukin 17 as a novel predictor of vascular function in rheumatoid arthritis,” Annals of the Rheumatic Diseases, vol. 70, no. 9, pp. 1550–1555, 2011. View at Publisher · View at Google Scholar · View at Scopus
  22. M. A. Gonzalez-Gay, C. Gonzalez-Juanatey, and J. Martin, “Inflammation and endothelial dysfunction in rheumatoid arthritis,” Clinical and Experimental Rheumatology, vol. 24, no. 2, pp. 115–117, 2006. View at Google Scholar · View at Scopus
  23. G. Murdaca, B. M. Colombo, P. Cagnati, R. Gulli, F. Spanò, and F. Puppo, “Endothelial dysfunction in rheumatic autoimmune diseases,” Atherosclerosis. In press. View at Publisher · View at Google Scholar · View at Scopus
  24. P. Libby, P. M. Ridker, and G. K. Hansson, “Progress and challenges in translating the biology of atherosclerosis,” Nature, vol. 473, no. 7347, pp. 317–325, 2011. View at Publisher · View at Google Scholar · View at Scopus
  25. I. Tabas, K. J. Williams, and J. Borén, “Subendothelial lipoprotein retention as the initiating process in atherosclerosis: update and therapeutic implications,” Circulation, vol. 116, no. 16, pp. 1832–1844, 2007. View at Publisher · View at Google Scholar · View at Scopus
  26. K. H. Yiu, S. Wang, M. Y. Mok et al., “Role of circulating endothelial progenitor cells in patients with rheumatoid arthritis with coronary calcification,” Journal of Rheumatology, vol. 37, no. 3, pp. 529–535, 2010. View at Publisher · View at Google Scholar · View at Scopus
  27. R. López-Mejías, C. González-Juanatey, M. García-Bermúdez et al., “The lp13.3 genomic region -rs599839- is associated with endothelial dysfunction in patients with rheumatoid arthritis,” Arthritis Research and Therapy, vol. 14, no. 2, article R42, 2012. View at Publisher · View at Google Scholar · View at Scopus
  28. M. García-Bermúdez, R. López-Mejías, C. González-Juanatey, A. Corrales, S. Castañeda, and J. A. Miranda-Filloy, “Association study of MIA3 rs17465637 polymorphism with cardiovascular disease in rheumatoid arthritis patients,” DNA and Cell Biology, vol. 31, no. 8, pp. 1412–1417, 2012. View at Google Scholar
  29. P. Libby, P. M. Ridker, and G. K. Hansson, “Inflammation in atherosclerosis: from pathophysiology to practice,” Journal of the American College of Cardiology, vol. 54, no. 23, pp. 2129–2138, 2009. View at Publisher · View at Google Scholar · View at Scopus
  30. M. Teruel, J. E. Martin, C. Gonzalez-Juanatey et al., “Association of acid phosphatase locus 1*C allele with the risk of cardiovascular events in rheumatoid arthritis patients,” Arthritis Research & Therapy, vol. 13, article R116, 2011. View at Publisher · View at Google Scholar · View at Scopus
  31. L. Rodríguez-Rodríguez, C. González-Juanatey, M. García-Bermúdez et al., “CCR5Δ32 variant and cardiovascular disease in patients with rheumatoid arthritis: a cohort study.,” Arthritis Research &; Therapy, vol. 13, no. 4, article R133, 2011. View at Google Scholar · View at Scopus
  32. R. Palomino-Morales, C. Gonzalez-Juanatey, T. R. Vazquez-Rodriguez et al., “A1298C polymorphism in the MTHFR gene predisposes to cardiovascular risk in rheumatoid arthritis,” Arthritis Research & Therapy, vol. 12, no. 2, article R71, 2010. View at Publisher · View at Google Scholar · View at Scopus
  33. R. Palomino-Morales, C. Gonzalez-Juanatey, T. R. Vazquez-Rodriguez et al., “Interleukin-6 gene -174 promoter polymorphism is associated with endothelial dysfunction but not with disease susceptibility in patients with rheumatoid arthritis,” Clinical and Experimental Rheumatology, vol. 27, no. 6, pp. 964–970, 2009. View at Google Scholar · View at Scopus
  34. L. Rodríguez-Rodríguez, C. González-Juanatey, R. Palomino-Morales et al., “TNFA -308 (rs1800629) polymorphism is associated with a higher risk of cardiovascular disease in patients with rheumatoid arthritis,” Atherosclerosis, vol. 216, no. 1, pp. 125–130, 2011. View at Publisher · View at Google Scholar · View at Scopus
  35. J. C. Vallvé, S. Paredes, J. Girona et al., “Tumor necrosis factor-α -1031 T/C polymorphism is associated with smaller and more proatherogenic low density lipoprotein particles in patients with rheumatoid arthritis,” Journal of Rheumatology, vol. 35, no. 9, pp. 1697–1703, 2008. View at Google Scholar · View at Scopus
  36. C. Gonzalez-Juanatey, A. Testa, A. Garcia-Castelo et al., “HLA-DRB1 status affects endothelial function in treated patients with rheumatoid arthritis,” American Journal of Medicine, vol. 114, no. 8, pp. 647–652, 2003. View at Publisher · View at Google Scholar · View at Scopus
  37. M. A. Gonzalez-Gay, C. Gonzalez-Juanatey, M. J. Lopez-Diaz et al., “HLA-DRB1 and persistent chronic inflammation contribute to cardiovascular events and cardiovascular mortality in patients with rheumatoid arthritis,” Arthritis Care and Research, vol. 57, no. 1, pp. 125–132, 2007. View at Publisher · View at Google Scholar · View at Scopus
  38. M. A. Gonzales-Gay, J. Llorca, R. Palomino-Morales, I. Gomez-Acebo, C. Gonzales-Juanatey, and J. Martin, “Influence of nitric oxide synthase gene polymorphisms on the risk of cardiovasular events in rheumatoid arthritis,” Clinical and Experimental Rheumatology, vol. 27, no. 1, pp. 116–119, 2009. View at Google Scholar · View at Scopus
  39. M. García-Bermúdez, R. López-Mejías, C. González-Juanatey, S. Castañeda, J. Miranda-Filloy, and R. Blanco, “Association of the methionine sulfoxide reductase A rs10903323 gene polymorphism with cardiovascular disease in patients with rheumatoid arthritis,” Scandinavian Journal of Rheumatology. In press.
  40. R. Palomino-Morales, C. Gonzalez-Juanatey, T. R. Vazquez-Rodriguez et al., “Lack of association of PTPN22, STAT4 and TRAF1/C5 gene polymorphisms with cardiovascular risk in rheumatoid arthritis,” Clinical and Experimental Rheumatology, vol. 28, no. 5, pp. 695–701, 2010. View at Google Scholar · View at Scopus
  41. R. López-Mejías, M. García-Bermúdez, C. González-Juanatey et al., “Lack of association of IL6R rs2228145 and IL6ST/gp130 rs2228044 gene polymorphisms with cardiovascular disease in patients with rheumatoid arthritis,” Tissue Antigens, vol. 78, no. 6, pp. 438–441, 2011. View at Publisher · View at Google Scholar · View at Scopus
  42. L. Rodríguez-Rodríguez, M. García-Bermúdez, C. González-Juanatey et al., “Vascular endothelial growth factor A and cardiovascular disease in rheumatoid arthritis patients,” Tissue Antigens, vol. 77, no. 4, pp. 291–297, 2011. View at Publisher · View at Google Scholar · View at Scopus
  43. M. García-Bermúdez, C. González-Juanatey, R. Lopez-Mejias et al., “Influence of MHCIITA rs3087456 and rs4774 polymorphisms in the susceptibility to cardiovascular disease of patients with rheumatoid arthritis,” Clinical and Experimental Rheumatology, vol. 30, no. 1, pp. 51–57, 2012. View at Google Scholar · View at Scopus
  44. R. Palomino-Morales, C. Gonzalez-Juanatey, T. R. Vazquez-Rodriguez et al., “Lack of association between macrophage migration inhibitory factor-173 gene polymorphism with disease susceptibility and cardiovascular risk in rheumatoid arthritis patients from northwestern Spain,” Clinical and Experimental Rheumatology, vol. 28, no. 1, pp. 68–72, 2010. View at Google Scholar · View at Scopus
  45. Y. Wada, T. Kuroda, A. Murasawa, N. Tanabe, M. Nakano, and F. Gejyo, “Autoantibodies against oxidized low-density lipoprotein (LDL) and carotid atherosclerosis in patients with rheumatoid arthritis,” Clinical and Experimental Rheumatology, vol. 23, no. 4, pp. 482–486, 2005. View at Google Scholar · View at Scopus
  46. M. J. L. Peters, V. P. Van Halm, M. T. Nurmohamed et al., “Relations between autoantibodies against oxidized low-density lipoprotein, inflammation, subclinical atherosclerosis, and cardiovascular disease in rheumatoid arthritis,” Journal of Rheumatology, vol. 35, no. 8, pp. 1495–1499, 2008. View at Google Scholar · View at Scopus
  47. H. M. M. S. Ahmed, M. Youssef, and Y. M. Mosaad, “Antibodies against oxidized low-density lipoprotein are associated with subclinical atherosclerosis in recent-onset rheumatoid arthritis,” Clinical Rheumatology, vol. 29, no. 11, pp. 1237–1243, 2010. View at Publisher · View at Google Scholar · View at Scopus
  48. N. Vuilleumier, J. Bratt, R. Alizadeh, T. Jogestrand, I. Hafström, and J. Frostegård, “Anti-apoA-1 IgG and oxidized LDL are raised in rheumatoid arthritis (RA): potential associations with cardiovascular disease and RA disease activity,” Scandinavian Journal of Rheumatology, vol. 39, no. 6, pp. 447–453, 2010. View at Publisher · View at Google Scholar · View at Scopus
  49. R. Gerli, E. B. Bocci, Y. Sherer, G. Vaudo, S. Moscatelli, and Y. Shoenfeld, “Association of anti-cyclic citrullinated peptide antibodies with subclinical atherosclerosis in patients with rheumatoid arthritis,” Annals of the Rheumatic Diseases, vol. 67, no. 5, pp. 724–725, 2008. View at Publisher · View at Google Scholar · View at Scopus
  50. A. M. El-Barbary, E. M. Kassem, M. A. S. El-Sergany, S. A. M. Essa, and M. A. Eltomey, “Association of anti-modified citrullinated vimentin with subclinical atherosclerosis in early rheumatoid arthritis compared with anti-cyclic citrullinated peptide,” Journal of Rheumatology, vol. 38, no. 5, pp. 828–834, 2011. View at Publisher · View at Google Scholar · View at Scopus
  51. J. Frostegård, “Low level natural antibodies against phosphorylcholine: a novel risk marker and potential mechanism in atherosclerosis and cardiovascular disease,” Clinical Immunology, vol. 134, no. 1, pp. 47–54, 2010. View at Publisher · View at Google Scholar · View at Scopus
  52. U. de Faire, J. Su, X. Hua et al., “Low levels of IgM antibodies to phosphorylcholine predict cardiovascular disease in 60-year old men: effects on uptake of oxidized LDL in macrophages as a potential mechanism,” Journal of Autoimmunity, vol. 34, no. 2, pp. 73–79, 2010. View at Publisher · View at Google Scholar · View at Scopus
  53. S. Ajeganova, C. Ehrnfelt, R. Alizadeh et al., “Longitudinal levels of apolipoproteins and antibodies against phosphorylcholine are independently associated with carotid artery atherosclerosis 5 years after rheumatoid arthritis onset—a prospective cohort study,” Rheumatology, vol. 50, no. 10, pp. 1785–1793, 2011. View at Google Scholar · View at Scopus
  54. C. S. Crowson, E. Myasoedova, J. M. Davis et al., “Increased prevalence of metabolic syndrome associated with rheumatoid arthritis in patients without clinical cardiovascular disease,” Journal of Rheumatology, vol. 38, no. 1, pp. 29–35, 2011. View at Publisher · View at Google Scholar · View at Scopus
  55. J. T. Giles, M. Allison, R. S. Blumenthal et al., “Abdominal adiposity in rheumatoid arthritis: association with cardiometabolic risk factors and disease characteristics,” Arthritis and Rheumatism, vol. 62, no. 11, pp. 3173–3182, 2010. View at Publisher · View at Google Scholar · View at Scopus
  56. A. C. Elkan, N. Håkansson, J. Frostegård, and I. Hafström, “Low level of physical activity in women with rheumatoid arthritis is associated with cardiovascular risk factors but not with body fat mass—a cross sectional study,” BMC Musculoskeletal Disorders, vol. 12, article 13, 2011. View at Publisher · View at Google Scholar · View at Scopus
  57. M. Pansuria, H. Xi, L. Li, X. F. Yang, and H. Wang, “Insulin resistance, metabolic stress, and atherosclerosis,” Frontiers in Bioscience, vol. 4, pp. 916–931, 2012. View at Google Scholar
  58. F. Atzeni, M. Turiel, R. Caporali et al., “The effect of pharmacological therapy on the cardiovascular system of patients with systemic rheumatic diseases,” Autoimmunity Reviews, vol. 9, no. 12, pp. 835–839, 2010. View at Publisher · View at Google Scholar · View at Scopus
  59. C. Chighizola, T. Schioppo, F. Ingegnoli, and P. L. Meroni, “Potential effect of anti-inflammatory treatment on reducing the cardiovascular risk in rheumatoid arthritis,” Curr Vasc Pharmacol. In press.
  60. R. S. Bresalier, R. S. Sandler, H. Quan et al., “Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial,” The New England Journal of Medicine, vol. 352, no. 11, pp. 1092–1102, 2005. View at Publisher · View at Google Scholar · View at Scopus
  61. M. Alacqua, G. Trifirò, L. Cavagna et al., “Prescribing pattern of drugs in the treatment of osteoarthritis in Italian general practice: the effect of rofecoxib withdrawal,” Arthritis Care and Research, vol. 59, no. 4, pp. 568–574, 2008. View at Publisher · View at Google Scholar · View at Scopus
  62. M. W. Van Der Linden, S. Van Der Bij, P. Welsing, E. J. Kuipers, and R. M. C. Herings, “The balance between severe cardiovascular and gastrointestinal events among users of selective and non-selective non-steroidal anti-inflammatory drugs,” Annals of the Rheumatic Diseases, vol. 68, no. 5, pp. 668–673, 2009. View at Publisher · View at Google Scholar · View at Scopus
  63. J. Metzner, L. Popp, C. Marian et al., “The effects of COX-2 selective and non-selective NSAIDs on the initiation and progression of atherosclerosis in ApoE-/- mice,” Journal of Molecular Medicine, vol. 85, no. 6, pp. 623–633, 2007. View at Publisher · View at Google Scholar · View at Scopus
  64. I. T. Padol and R. H. Hunt, “Association of myocardial infarctions with COX-2 inhibition may be related to immunomodulation towards a Th1 response resulting in atheromatous plaque instability: an evidence-based interpretation,” Rheumatology, vol. 49, no. 5, pp. 837–843, 2010. View at Google Scholar · View at Scopus
  65. M. Raval, P. G. Frank, L. Laury-Kleintop, G. Yan, and S. Lanza-Jacoby, “Celecoxib combined with atorvastatin prevents progression of atherosclerosis,” Journal of Surgical Research, vol. 163, no. 2, pp. e113–e122, 2010. View at Publisher · View at Google Scholar · View at Scopus
  66. J. M. Gitlin and C. D. Loftin, “Cyclooxygenase-2 inhibition increases lipopolysaccharide-induced atherosclerosis in mice,” Cardiovascular Research, vol. 81, no. 2, pp. 400–407, 2009. View at Publisher · View at Google Scholar · View at Scopus
  67. J. K. Dabhi, J. K. Solanki, and A. Mehta, “Antiatherosclerotic activity of ibuprofen, a non-selective COX inhibitor- An animal study,” Indian Journal of Experimental Biology, vol. 46, no. 6, pp. 476–481, 2008. View at Google Scholar · View at Scopus
  68. E. Morrison and H. A. Capell, “Corticosteroids in the management of early and established rheumatoid disease,” Rheumatology, vol. 45, no. 9, pp. 1058–1061, 2006. View at Publisher · View at Google Scholar · View at Scopus
  69. R. C. Andrews and B. R. Walker, “Glucocorticoids and insulin resistance: old hormones, new targets,” Clinical Science, vol. 96, no. 5, pp. 513–523, 1999. View at Publisher · View at Google Scholar · View at Scopus
  70. J. A. Whitworth, G. J. Mangos, and J. J. Kelly, “Cushing, cortisol, and cardiovascular disease,” Hypertension, vol. 36, no. 5, pp. 912–916, 2000. View at Google Scholar · View at Scopus
  71. A. Ruyssen-Witrand, B. Fautrel, A. Saraux, X. Le Loët, and T. Pham, “Cardiovascular risk induced by low-dose corticosteroids in rheumatoid arthritis: a systematic literature review,” Joint Bone Spine, vol. 78, no. 1, pp. 23–30, 2011. View at Publisher · View at Google Scholar · View at Scopus
  72. I. Hafström, M. Rohani, S. Deneberg, M. Wörnert, T. Jogestrand, and J. Frostegård, “Effects of low-dose prednisolone on endothelial function, atherosclerosis, and traditional risk factors for atherosclerosis in patients with rheumatoid arthritis—a randomized study,” Journal of Rheumatology, vol. 34, no. 9, pp. 1810–1816, 2007. View at Google Scholar · View at Scopus
  73. H. Mäkinen, H. Kautiainen, P. Hannonen et al., “Sustained remission and reduced radiographic progression with combination disease modifying antirheumatic drugs in early rheumatoid arthritis,” Journal of Rheumatology, vol. 34, no. 2, pp. 316–321, 2007. View at Google Scholar · View at Scopus
  74. F. Breedveld, “The value of early intervention in RA-a window of opportunity,” Clinical Rheumatology, vol. 30, supplement 1, pp. S33–S39, 2011. View at Publisher · View at Google Scholar · View at Scopus
  75. R. B. M. Landewé, B. E. E. M. Van Den Borne, F. C. Breedveld, and B. A. C. Dijkmans, “Methotrexate effects in patients with rheumatoid arthritis with cardiovascular comorbidity,” The Lancet, vol. 355, no. 9215, pp. 1616–1617, 2000. View at Google Scholar · View at Scopus
  76. H. K. Choi, M. A. Hernán, J. D. Seeger, J. M. Robins, and F. Wolfe, “Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study,” The Lancet, vol. 359, no. 9313, pp. 1173–1177, 2002. View at Publisher · View at Google Scholar · View at Scopus
  77. S. L. Westlake, A. N. Colebatch, J. Baird et al., “The effect of methotrexate on cardiovascular disease in patients with rheumatoid arthritis: a systematic literature review,” Rheumatology, vol. 49, no. 2, pp. 295–307, 2009. View at Publisher · View at Google Scholar · View at Scopus
  78. A. Bulgarelli, A. A. Martins Dias, B. Caramelli, and R. C. Maranhão, “Treatment with methotrexate inhibits atherogenesis in cholesterol-fed rabbits,” Journal of Cardiovascular Pharmacology, vol. 59, no. 4, pp. 308–314, 2012. View at Publisher · View at Google Scholar · View at Scopus
  79. D. H. Solomon, J. Avorn, J. N. Katz et al., “Immunosuppressive medications and hospitalization for cardiovascular events in patients with rheumatoid arthritis,” Arthritis and Rheumatism, vol. 54, no. 12, pp. 3790–3798, 2006. View at Publisher · View at Google Scholar · View at Scopus
  80. M. Kockx, W. Jessup, and L. Kritharides, “Cyclosporin A and atherosclerosis—cellular pathways in atherogenesis,” Pharmacology and Therapeutics, vol. 128, no. 1, pp. 106–118, 2010. View at Publisher · View at Google Scholar · View at Scopus
  81. C. E. Tabit, M. Holbrook, S. M. Shenouda et al., “Effect of sulfasalazine on inflammation and endothelial function in patients with established coronary artery disease,” Vascular Medicine, vol. 17, no. 2, pp. 101–107, 2012. View at Publisher · View at Google Scholar · View at Scopus
  82. J. M. Dayer, “The saga of the discovery of IL-1 and TNF and their specific inhibitors in the pathogenesis and treatment of rheumatoid arthritis,” Joint Bone Spine, vol. 69, no. 2, pp. 123–132, 2002. View at Publisher · View at Google Scholar · View at Scopus
  83. M. A. Gonzales-Gay, M. T. Garcia-Unzueta, J. M. De Matias et al., “Influence of anti-TNF-α infliximab therapy on adhesion molecules associated with atherogenesis in patients with rheumatoid arthritis,” Clinical and Experimental Rheumatology, vol. 24, no. 4, pp. 373–379, 2006. View at Google Scholar · View at Scopus
  84. N. Komai, Y. Morita, T. Sakuta, A. Kuwabara, and N. Kashihara, “Anti-tumor necrosis factor therapy increases serum adiponectin levels with the improvement of endothelial dysfunction in patients with rheumatoid arthritis,” Modern Rheumatology, vol. 17, no. 5, pp. 385–390, 2007. View at Publisher · View at Google Scholar · View at Scopus
  85. Z. Szekanecz, G. Kerekes, and P. Soltész, “Vascular effects of biologic agents in RA and spondyloarthropathies,” Nature Reviews Rheumatology, vol. 5, no. 12, pp. 677–684, 2009. View at Publisher · View at Google Scholar · View at Scopus
  86. C. I. Daïen, Y. Duny, T. Barnetche, J.-P. Daurès, B. Combe, and J. Morel, “Effect of TNF inhibitors on lipid profile in rheumatoid arthritis: a systematic review with meta-analysis,” Annals of the Rheumatic Diseases, vol. 71, no. 6, pp. 862–868, 2012. View at Publisher · View at Google Scholar · View at Scopus
  87. M. A. Gonzalez-Gay, C. Gonzalez-Juanatey, T. R. Vazquez-Rodriguez, J. A. Miranda-Filloy, and J. Llorca, “Insulin resistance in rheumatoid arthritis: the impact of the anti-TNF-α therapy: annals of the New York Academy of Sciences,” Annals of the New York Academy of Sciences, vol. 1193, pp. 153–159, 2010. View at Publisher · View at Google Scholar · View at Scopus
  88. M. A. Gonzalez-Gay, M. T. Garcia-Unzueta, C. Gonzalez-Juanatey et al., “Anti-TNF-α therapy modulates resistin in patients with rheumatoid arthritis,” Clinical and Experimental Rheumatology, vol. 26, no. 2, pp. 311–316, 2008. View at Google Scholar · View at Scopus
  89. D. Hürlimann, A. Forster, G. Noll et al., “Anti-tumor necrosis factor-α treatment improves endothelial function in patients with rheumatoid arthritis,” Circulation, vol. 106, no. 17, pp. 2184–2187, 2002. View at Publisher · View at Google Scholar · View at Scopus
  90. C. Gonzalez-Juanatey, J. Llorca, A. Sanchez Andrade, C. Garcia-Porrua, J. Martin, and M. A. Gonzalez-Gay, “Short-term adalimumab therapy improves endothelial function in patients with rheumatoid arthritis refractory to infliximab,” Clinical and Experimental Rheumatology, vol. 24, no. 3, pp. 309–312, 2006. View at Google Scholar · View at Scopus
  91. P. Sarzi-Puttini, F. Atzeni, Y. Shoenfeld, and G. Ferraccioli, “TNF-α, rheumatoid arthritis, and heart failure: a rheumatological dilemma,” Autoimmunity Reviews, vol. 4, no. 3, pp. 153–161, 2005. View at Publisher · View at Google Scholar · View at Scopus
  92. G. Kerekes, P. Soltész, H. Dér et al., “Effects of rituximab treatment on endothelial dysfunction, carotid atherosclerosis, and lipid profile in rheumatoid arthritis,” Clinical Rheumatology, vol. 28, no. 6, pp. 705–710, 2009. View at Publisher · View at Google Scholar · View at Scopus
  93. C. Gonzalez-Juanatey, J. Llorca, T. R. Vazquez-Rodriguez, N. Diaz-Varela, H. Garcia-Quiroga, and M. A. Gonzalez-Gay, “Short-term improvement of endothelial function in rituximab-treated rheumatoid arthritis patients refractory to tumor necrosis factor α blocker therapy,” Arthritis Care and Research, vol. 59, no. 12, pp. 1821–1824, 2008. View at Publisher · View at Google Scholar · View at Scopus
  94. M. J. L. Peters, D. P. M. Symmons, D. McCarey et al., “EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis,” Annals of the Rheumatic Diseases, vol. 69, no. 2, pp. 325–331, 2010. View at Publisher · View at Google Scholar · View at Scopus
  95. L. E. Full and C. Monaco, “Targeting inflammation as a therapeutic strategy in accelerated atherosclerosis in rheumatoid arthritis,” Cardiovascular Therapeutics, vol. 29, no. 4, pp. 231–242, 2011. View at Publisher · View at Google Scholar · View at Scopus
  96. M. A. González-Gay, C. González-Juanatey, and J. Llorca, “Carotid ultrasound in the cardiovascular risk stratification of patients with rheumatoid arthritis: when and for whom?” Annals of the Rheumatic Diseases, vol. 71, no. 6, pp. 796–798, 2012. View at Publisher · View at Google Scholar · View at Scopus
  97. X. Sheng, M. J. Murphy, T. M. MacDonald, and L. Wei, “Effectiveness of statins on total cholesterol and cardiovascular disease and all-cause mortality in osteoarthritis and rheumatoid arthritis,” Journal of Rheumatology, vol. 39, no. 1, pp. 32–40, 2012. View at Publisher · View at Google Scholar · View at Scopus